Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 2

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Keratosis, Actinic 2Carcinoma, Basal Cell 1

Interventions

Cisplatin 187Carboplatin 182Paclitaxel 177Docetaxel 145Cyclophosphamide 129Dexamethasone 117pembrolizumab 106Doxorubicin 103Bevacizumab 103Gemcitabine 102Rituximab 96Prednisone 87Fluorouracil 86Pemetrexed 82Radiotherapy 77Vincristine 71Etoposide 71Capecitabine 69Nivolumab 68Trastuzumab 67Leucovorin 64Cytarabine 57Methotrexate 52Oxaliplatin 49atezolizumab 48Lenalidomide 43Ipilimumab 40Filgrastim 40Bortezomib 39Sorafenib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Has results × BF-200 ALA × Clear all
NCT02144077 2022-11-03

Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy

Biofrontera Bioscience GmbH

Phase 3 Completed
281 enrolled 16 charts
Dermatologic

Carcinoma, Basal Cell

NCT02799069 2017-04-28

Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy

Biofrontera Bioscience GmbH

Phase 3 Completed
571 enrolled 46 charts
Dermatologic

Keratosis, Actinic

NCT02799082 2017-04-06

Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.

Biofrontera Bioscience GmbH

Phase 3 Completed
122 enrolled 24 charts
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡